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Abstract
Background: Alzheimer’s disease (AD) is a globally prevalent neurodegenerative condition, clinically characterized
by progressive memory loss and gradual impairment of cognitive functions. Bapineuzumab is a fully humanized
monoclonal antibody that binds to neurotoxic amyloid proteins in the brain, enhancing their clearance. We
performed this systematic review and meta-analysis to evaluate the safety and efficacy of bapineuzumab in patients
with mild to moderate Alzheimer’s disease.
Methods: We performed a web-based literature search of PubMed, Ovid, EBSCO, Scopus, Embase, Cochrane
CENTRAL, and web of science using the relevant keywords. Data were extracted from eligible records and pooled
as mean difference (MD) or risk ratio (RR) values with their 95% confidence interval (CI), using Review Manager
software (version 5.3 for windows). Heterogeneity was measured by Chi-square and I-square tests.
Result: The pooled effect estimate from six randomized clinical trials (n = 2380) showed that bapineuzumab
significantly reduced the cerebrospinal fluid concentration of phosphorylated tau proteins (Standardized MD = −5.53,
95% CI [−8.29, −2.76]). However, the bapineuzumab group was not superior to the placebo group in terms of change
from baseline in Alzheimer’s disease assessment scale (ADAS)-Cog11 (MD = 0.14, 95% CI [−0.72, 0.99]), disability
assessment for dementia (DAD) scale (MD = 1.35, 95% CI [−1.74, 4.43]), and mini-mental state examination (MMSE)
scores (MD = 0.08, 95% CI [−0.31, 0.47]). Regarding safety, bapineuzumab increased the risk of serious treatment-
emergent adverse events (RR = 1.18, 95% CI [1.02, 1.37]) and cerebral vasogenic edema (RR = 40.88, 95% CI [11.94, 135.
95]). All bapineuzumab doses (0.15, 0.5, 1, and 2 mg/kg) were similar to placebo in terms of change from baseline in
ADAS-cog11, DAD, and MMSE scores, except for the 0.15 mg/kg dose, which caused a significant worsening on the
ADAS-cog11 scale (MD = 5.6, 95% CI [0.22, 10.98]).
Conclusions: Considering the lack of clinical efficacy, combined with the significant association with serious adverse
events, bapineuzumab should not be used to treat patients with mild to moderate AD. Future studies should
investigate the effect of combining bapineuzumab with other therapeutic strategies and reevaluate the efficacy of
targeting amyloid β proteins in AD therapy.
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Background
Alzheimer’s Disease (AD) is a neurodegenerative condi-
tion, clinically characterized by progressive memory loss
and gradual impairment of cognitive functions [1]. The
pathological hallmarks of the disease include cerebral
neuronal loss, cerebral plaques due to accumulation of
extracellular amyloid β (Aβ) proteins, and intraneuronal
neurofibrillary tangles [2–4]. The current annual inci-
dence of AD is 1275 new cases per 100,000 patients [5]
and the prevalence is expected to reach more than 140
million patients in 2050 [6]. Current therapeutic strategies
only aim at improving the symptoms by improving neuro-
transmitter levels in the surviving neuronal circuitry [7].
Babineuzumab (AAB-001) is a fully - humanized, N-
terminal specific anti-Aβ monoclonal antibody, which
binds to neurotoxic amyloid proteins in the brain, en-
hancing their clearance [8]. Preclinical trials have shown
that passive immunotherapy with monoclonal antibodies
was associated with a significant reduction of Aβ protein
levels in the brain and memory improvement in trans-
genic mice with Aβ proteins overproduction [8–12]. Fur-
thermore, phase II clinical trials have shown that
bapineuzumab can reduce the load of amyloid proteins
on positron emission tomography (PET) and the con-
centration of phosphorylated tau proteins in the cere-
brospinal fluid [13, 14].
Within the past few years, several phase II and phase
III clinical trials have investigated the role of bapineuzu-
mab in improving the clinical and biomarker outcomes
of AD [13–17]. The purpose of this systematic review
and meta-analysis is to synthesize evidence from pub-
lished, randomized, controlled trials regarding the safety
and efficacy of bapineuzumab in the treatment of pa-
tients with mild to moderate AD.
Methods
We followed the PRISMA statement guidelines during the
preparation of this systematic review and meta-analysis.
Moreover, all steps were performed in a strict accordance
to the Cochrane handbook of systematic reviews of inter-
ventions [18].
Literature search strategy
We searched for published, randomized, controlled trials
in medical electronic databases including: PubMed, Ovid,
EBSCO, Scopus, Embase, Cochrane central register of
clinical trials (CENTRAL), and web of science through
April 2016, using the following query: “Bapineuzumab OR
AAB-001 AND Alzheimer OR Dementia”. We also
checked the clinical trial registry (Clinicaltrials.gov) for
additional ongoing and unpublished studies. No language
or time restrictions were imposed. Furthermore, we hand-
searched the reference list of included studies for any
missed trials.
Eligibility criteria and study selection
We used the following inclusion criteria:
(1)Study design: randomized controlled trials
comparing bapineuzumab with placebo.
(2)Intervention:
➢ Drug: Bapineuzumab
➢ Dose: 0.15, 0.5, 1, or 2 mg/kg. Other doses were
not adequately reported in included studies;
therefore, there were not eligible for quantitative
analysis.
➢ Preparation/route of administration: Intravenous
infusion.
(3)Comparator: placebo (control group).
(4)Population: Patients with mild to moderate AD
(MMSE score between 14 and 26 and Rosen
Modified Hachinski Ischemic score < 4). Patients
were excluded if they had another clinically
significant neurological disease.
(5)Outcomes: Efficacy endpoints included clinical and
key biomarker outcomes. Safety endpoints included
commonly reported adverse events in the analyzed
trials.
We excluded observational studies, animal studies,
non-randomized trials, studies with unreliable data
extraction, thesis, and conference abstracts. Two in-
dependent authors (AA, RS) screened the title and
abstract of retrieved records for relevance to the re-
view subject. Full texts of potentially relevant studies
were retrieved and reviewed for eligibility to meta-
analysis.
Data extraction
Two authors (AIA, RF) extracted the data independently
using a formatted data extraction sheet. A consensus be-
tween the review authors was obtained to prevent any
misinterpretation of extracted data and any conflicts were
resolved upon the opinion of a third reviewer (AE). The
extracted data included the following: 1) criteria of study
design, 2) characteristics of enrolled patients, 3) study out-
comes including:
A. Efficacy outcomes:
➢ Clinical outcomes included change from
baseline scores in the 11-item cognitive subscale
of the Alzheimer’s Disease Assessment Scale
(ADAS-cog11: with scores between 0 and 70;
higher scores indicate greater impairment [19]),
the Disability Assessment for Dementia (DAD:
scale with scores between 0 and 100; higher
scores indicate less impairment [20]), clinical de-
mentia rating scale-sum of boxes (CDR-SOB: with
scores between 0 and 18; higher scores indicate
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greater impairment [21]), neuropsychological bat-
tery test score (which is scored on a standardized
z scale; higher scores indicate less impairment
[22]), mini-mental state examination (MMSE), and
dependence scale (with scores between 0 and 15;
higher scores indicate greater assistance require-
ments [23]).
➢ Key biomarker outcomes included brain
amyloid burden, measured by Pittsburgh
compound B- Positron emission tomography
(PIB-PET) and calculated as the average
standardized uptake value ratio (SUVR) of
cortical regions, cerebrospinal fluid
phosphorylated-tau protein concentration (pg/
ml), and the annual rate of brain volume loss,
measured by volumetric MRI.
B. Safety outcomes included the frequency of serious
treatment emergent adverse events (TEAEs), fatal
adverse events, amyloid related imaging
abnormalities (vasogenic edema), delirium,
headache, and convulsions.
Data for continuous outcomes (efficacy endpoints)
were extracted as change score (mean difference or
change from baseline to the treatment endpoint [week
78]) and standard deviation, while data for dichotom-
ous outcomes (safety endpoints) were extracted as the
number of events in each study group, compared to the
total number of enrolled patients within that group.
When the standard deviation (SD) of mean change
from baseline was missing, it was calculated from the
standard error (SE) or 95% confidence interval (CI)
according to Altman equations [24].
Risk of bias assessment
Two authors (AIA, SF) independently assessed the risk
of bias in included studies, in accordance with the
Cochrane handbook of systematic reviews of interven-
tions (5.1.0). Due to the small number of included
studies, publication bias could not be assessed using




























After Full Text Screening
n 5 pharmacokinetic analysis
n 10 secondary report
n 4 abstracts
n 5 literature reviews
n 3 correspondence
n 1 In vitro study
n 1 non-randomized study
n 1 study protocol
6 studies with 5 Articles Included
Fig. 1 PRISMA flow diagram of studies’ screening and selection
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Data synthesis
Changes in efficacy outcomes were pooled as mean dif-
ference (MD) or standardized mean difference (SMD)
values and the frequency of adverse events was pooled
as risk ratio (RR) values with a confidence interval of
95% in a meta-analysis model. Statistical analysis was
conducted by Review Manager (RevMan) software
(version 5.3 for windows). The results were considered
statistically significant if the p value was less than 0.05.
Heterogeneity among included studies was measured
by the Chi-Square test and the I-Square test was used
to quantify its extent. In case of significant heterogen-
eity (Chi-Square p < 0.1 or I2 > 50%), the analysis was
conducted under the random effects model; otherwise, a
fixed effect model was used.
Results
Our search retrieved 1503 unique records. Thirty five
full text articles were screened for eligibility, from
which 30 articles were excluded. Six unique studies
(five reports with 2380 patients) were included in the
final analysis. (See PRISMA flow diagram; Fig. 1). Rea-
sons for study exclusion are shown in Additional file 1.
A summary of included studies and their primary re-
sults are shown in Table 1 and baseline characteristics
of their enrolled patients are shown in Table 2.
The risk of bias in included studies was low according
to the Cochrane risk of bias assessment tool. A summary
of risk of bias assessment domains for included studies
is shown in Fig. 2 and the authors’ judgments with justi-
fications are shown in Additional file 2.
I. Efficacy endpoints:
A. Clinical outcomes:
1. Alzheimer’s Disease Assessment Scale- Cognitive
subscale score:
The pooled effect size showed no significant
difference between bapineuzumab and placebo
groups in terms of change in ADAS-cog11 score
from baseline to the treatment endpoint [week 78]
(MD = 0.14, 95% CI [−0.72, 0.99], p = 0.75); Fig.
3a. Pooled studies were homogenous (I2 = 25%,
p = 0.26).
2. Disability assessment for dementia score:
The pooled effect size showed no significant
difference between bapineuzumab and placebo
groups in terms of change in DAD score from
baseline to the treatment endpoint [week 78]
(MD = 1.35, 95% CI [−1.74, 4.43], p = 0.39); Fig.
3b. Pooled studies were heterogenous (I2 = 54%,
p = 0.09); therefore, the analysis was performed
under the random effects model.
3. Clinical Dementia Rating Scale – Sum of boxes
(CDR-SOB):
The pooled effect size showed no significant
difference between bapineuzumab and placebo
groups in terms of change in CDR-SOB score
from baseline to the treatment endpoint [week
78] (MD = 0.21, 95% CI [−0.07, 0.49], p = 0.14);
Fig. 3c. Pooled studies were homogenous
(I2 = 0%, p = 0.47).
4. Neuropsychological Battery test Score:
The pooled effect size showed no significant
difference between bapineuzumab and placebo
groups in terms of change in neuropsychological
battery test score from baseline to the treatment
endpoint [week 78] (MD = 0.0, 95% CI [−0.05,
0.05], p = 1); Fig. 3d. Pooled studies were
homogenous (I2 = 0%, p = 0.53).
5. Mini Mental State Examination (MMSE):
The pooled effect size showed no significant
difference between bapineuzumab and placebo
groups in terms of change in MMSE score from
baseline to the treatment endpoint [week 78]
(MD = 0.08, 95% CI [−0.31, 0.47], p = 0.68); Fig. 3e.
Pooled studies were homogenous (I2 = 0%, p = 0.51).
6. Dependence scale score:
The pooled effect size showed no significant
difference between bapineuzumab and placebo
groups in terms of change in the dependence test
score from baseline to the treatment endpoint
[week 78] (MD = 0.10, 95% CI [−0.10, 0.31],
p = 0.31); Fig. 3f. Pooled studies were
homogenous (I2 = 0%, p = 0.33).
B. Key biomarker outcomes:
1. CSF Phosphorylated tau concentration:
The overall effect estimate showed that
bapineuzumab significantly reduced CSF tau-p con-
centrations at treatment endpoint [week 78],
Fig. 2 Risk of bias summary generated by RevMan software
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compared to placebo (SMD = −5.04, 95% CI [−8,
−2.09], p = 0.0008); Fig. 4a. Pooled studies were
homogenous (I2 = 24%, p = 0.26).
2. SUVR Measured by PIB-PET:
The overall effect estimate showed no significant
difference between bapineuzumab and placebo
groups in terms of SVUR change from baseline to
the treatment endpoint [week 78] (SMD = −0.56,
95% CI [−1.24, 0.13], p = 0.11); Fig. 4b. Pooled
studies were heterogenous (I2 = 72%, p = 0.03);








Fig. 3 Forest plot of mean difference (MD) in a Alzheimer disease assessment scale - Cognitive subscale 11 items, b Disability assessment for
dementia, c Clinical dementia rating scale – Sum of boxes, d Neuropsychological Battery test Score, e Mini Mental State Examination, and
f Dependence scale score
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3. MRI whole-brain volume measurement:
The overall effect estimate showed no significant
difference between bapineuzumab and placebo
groups in terms of change of whole brain volume
measurement from baseline to the treatment
endpoint [week 78] (SMD = 0.09, 95% CI [−0.02,
0.21], p = 0.12); Fig. 4c. Pooled studies were
homogenous (I2 = 0%, p = 0.54).
II. Safety endpoints:
The total incidence of adverse events was
significantly higher in the bapineuzumab group,
compared to the placebo group (RR = 1.31, 95%
CI [1.18, 1.45], p < 0.00001). In terms of
individual adverse events, the incidence of serious
TEAEs (RR = 1.18, 95% CI [1.02, 1.37], p = 0.03)
and amyloid-related imaging abnormalities (vaso-
genic edema) (RR = 40.88, 95% CI [11.94, 139.95],
p < 0.00001) was significantly higher in the bapi-
neuzumab group, compared to the placebo group.
However, the overall risk ratio did not favor ei-
ther of the two groups in terms of the frequency
of neoplasms (RR = 2.42, 95% CI [0.57, 10.28],
p = 0.23), fatal adverse events (RR = 1.32, 95% CI
[0.73, 2.40], p = 0.36), headache (RR = 1.03, 95%
CI [0.81, 1.32], p = 0.8), vomiting (RR = 0.92,
95% CI [0.55, 1.55], p = 0.76), delirium (RR = 2.21,
95% CI [0.36, 13.53], p = 0.39), hypertension
(RR = 0.49, 95% CI [0.12, 2.12], p = 0.34),
convulsions (RR = 2.24, 95% CI [0.76, 6.58],
p = 0.14), and falls (RR = 0.98, 95% CI [0.80,
1.21], p = 0.86); Fig. 5. For all adverse events,
pooled studies were homogenous (Chi-Square
p > 0.1).
III.Subgroup analysis
A stratification analysis was performed to
investigate the effect of individual doses of
bapineuzumab on the clinical outcomes. All
bapineuzumab doses (0.15, 0.5, 1, and 2 mg/kg)
were similar to placebo in terms of change from
baseline in ADAS-cog11, DAD, and MMSE scores,
except for the 0.15 mg/kg dose, which caused a
significant worsening on the ADAS-cog11
(MD = 5.6, 95% CI [0.22, 10.98], p = 0.04); Fig. 6.
In APOE-4 carriers, bapineuzumab was significantly
associated with vasogenic edema (RR = 39.36, 95%
CI [9.82, 157.78], p < 0.00001), compared to pla-
cebo. Pooled studies [13, 16, 26] were
homogenous (I2 = 52%, p = 0.12). In APOE-4
non-carriers, bapineuzumab was less significantly
associated with vasogenic edema (RR = 8.45, 95%
CI [1.61, 44.26], p = 0.01), in comparison to
placebo. Pooled studies [13, 16, 26] were
homogenous (I2 = 0%, p = 0.52).
Discussion
Evaluation of the therapeutic efficacy of anti-Aβ monoclo-
nal antibodies in AD depends primarily on cognitive and
functional outcomes, while measurement of CSF bio-
markers and neuroimaging techniques can only supple-




Fig. 4 Forest plot of mean difference (MD) in a CSF phosphorylated tau protein concentration, b Standardized uptake value ratio, measured by
PIB-PET, and c MRI whole-brain volume measurement
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Fig. 5 Forest plots of risk ratio (RR) of adverse events
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number of phase II and phase III clinical trials in this
regard over the past decade. However, this is the first
systematic review and meta-analysis about the safety and
efficacy of a monoclonal antibody in patients with mild to
moderate AD. Our analysis showed that bapineuzumab
can effectively reduce CSF phosphorylated tau protein
concentration; however, this was not translated into im-
proved clinical outcomes. Moreover, bapineuzumab sig-
nificantly increased the risk of serious TEAEs and amyloid
related imaging abnormalities in comparison to placebo.
Our results are consistent with the findings of a
pooled analysis of two phase II clinical trials that showed
that bapineuzumab can efficiently reduce CSF phosphor-
ylated tau protein concentration [28]. This effect was
more pronounced in APOE-4 carrier patients; a finding
that was later confirmed in phase III trials [16]. Explora-
tory analysis in phase II studies showed favorable thera-
peutic trends on ADAS-Cog and DAD scales [13, 27];
however, phase III studies with larger sample sizes found
no evidence of similar therapeutic effects [16]. The find-
ing that the biological effect of lowering CSF phosphory-
lated tau protein concentration was not translated into
improved clinical outcomes can be attributed to a variety
of reasons. It is possible that the quantity of amyloid
removal is not sufficient or that an important species of
Aβ proteins was not adequately targeted. It is also
possible that Aβ proteins are not the ideal target for
therapeutic interventions. Because amyloid deposition in
the brain starts years before the appearance of symp-
toms, Sperling et al. hypothesized that targeting these
proteins after development of dementia may be too late
to improve clinical outcomes [29]. These hypotheses
need further verification to develop new treatments that
can adequately target the etiology of the disease.
The failure of bapineuzumab to improve clinical out-
comes in AD patients appears to be inherent to the targeted
therapeutic mechanism rather than the drug itself or its
route of administration. A recent study by Novak et al.
showed that subcutaneous injection of bapineuzumab at
doses ranging from 2 to 20 mg for 12 months failed to
demonstrate a significant improvement of clinical out-
comes; however, it showed a lower incidence of vasogenic
edema, in comparison to studies that have utilized the
intravenous route [31]. Two phase III trials have shown that
solanezumab, another monoclonal antibody that targets Aβ
proteins (administered intravenously at a dose of 400 mg
every 4 weeks), did not affect the clinical outcomes in pa-
tients with moderate AD, but showed a potential clinical ef-
fect in mild AD [30]. We are aware of few ongoing phase
III trials about gantenerumab (administered intravenously
at a dose range of 60 to 200 mg every 4 weeks), which is
the first fully - humanized monoclonal antibody to target
both the N-terminal and central region of Aβ proteins.
The findings from our analysis indicated that bapineu-
zumab had no significant impact on the brain amyloid
burden, measured by Pittsburgh compound B- Positron
emission tomography (PIB-PET). Although this may
contradict with our aforementioned finding that bapi-
neuzumab reduces CSF p-tau protein concentration, the
value of PIB-PET in diagnosis and therapeutic follow up
of patients with AD is generally doubtable. Both phase
III trials about bapineuzumab and solanezumab showed
that around 25% of patients had negative PIB-PET scans
at baseline, indicating that they did not have AD from
Fig. 6 Stratification analysis of different bapineuzumab doses in terms of their effect on ADAS-Cog 11
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the start [32]. Future trials are recommended to incorp-
orate amyloid thresholds in their eligibility criteria [16].
In terms of safety, our analysis showed that bapineuzu-
mab increases the risk of cerebral vasogenic edema. Four
included studies (three reports), along with our analysis,
showed that bapineuzumab-induced vasogenic edema was
more frequent in APOE-4 carriers and higher dose groups
[13, 16, 32]. The etiology of vasogenic edema is still ob-
scure, but it may be related to vascular amyloid burden.
The finding that amyloid deposition is more extensive in
APOE-4 carriers’ cerebral blood vessels than those of non-
carriers supports that theory [33]. Moreover, pre-existing
cerebral amyloid angiopathy may slow drainage of intersti-
tial fluid after mobilization of Aβ proteins [34]. However, all
of these studies reported that vasogenic edema resolved on
MRI upon dose adjustment or discontinuation of treat-
ment. According to our analysis, the risk of serious TEAEs
was significantly higher in bapineuzumab treated patients,
compared to control patients. These disadvantages, com-
bined with the lack of clinical benefits, stand against further
clinical development of bapineuzumab.
The low risk of bias in the included double-blinded,
randomized, controlled trials adds to the credibility of
our evidence. A stratification analysis was performed to
evaluate the efficacy of individual doses in comparison
to placebo. We performed all steps in strict accordance
to the Cochrane handbook of systematic reviews and re-
ported them according to the preferred reporting items
for systematic reviews and meta-analysis (PRISMA)
statement guidelines.
The generalization of our results can be limited by
the small number of available trials, offering a re-
latively small number of patients. Although we could
not statistically assess for publication bias, we are
aware of several related studies that were registered
on clinicaltrials.gov, but were terminated before
completion after the publication of the negative re-
sults of phase III trials. There were 762 (32%) dis-
continuations in the included studies; however, we
believe this is unlikely to influence our results be-
cause all studies analyzed their data in an intention
to treat approach.
Future randomized trials should investigate the safety
and efficacy of combining bapineuzumab or other mono-
clonal antibodies with other therapeutic strategies for de-
mentia. Further resources should be allocated to basic
neuroscience research to expand the understanding of the
basic pathological mechanisms of AD and target them
with novel therapeutic strategies.
Conclusions
Although bapineuzumab effectively reduced CSF phosphor-
ylated tau protein concentration, this was not translated
into improved clinical outcomes. Moreover, bapineuzumab
significantly increased the risk of serious TEAEs and amyl-
oid related imaging abnormalities. In light of the current
evidence, bapineuzumab should not be used to treat pa-
tients with mild to moderate AD. Future studies should in-
vestigate the effect of combining bapineuzumab with other
therapeutic strategies and reevaluate the efficacy of target-
ing amyloid β proteins in AD therapy.
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